This is a routine director sale following an option exercise — no material signal. Monitor for actual Form 4 filings to confirm whether the sale was executed. The small size relative to market cap and director status (not CEO/CFO) suggests no bearish read-through.
Price Chart
Executive Summary
Director Jakob Dupont filed a Form 144 on June 30, 2026, indicating intent to sell 35,000 shares of Pyxis Oncology common stock, valued at approximately $107,034. The shares were acquired via a stock option exercise on the same day. This is a routine director sale following an option exercise and does not signal a change in company fundamentals.
Key Facts
- Director Jakob Dupont filed Form 144 to sell 35,000 shares of Pyxis Oncology common stock.
- Estimated sale value is approximately $107,034 based on the filing date.
- Shares were acquired via stock option exercise on June 30, 2026.
- The sale is to be executed through Fidelity Brokerage Services LLC.
- The filing represents intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 35,000 shares valued at ~$107K, representing ~0.06% of shares outstanding (based on 63.4M shares outstanding per filing).
Risk Factors
- Insider sale could be perceived negatively by retail traders despite routine nature.
- If additional insider sales cluster in coming weeks, it could signal reduced confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004977 |
| Document: 0001959173-26-004977-index.html | 0001959173-26-004977 |
| Document: 0001959173-26-004977.txt | 0001959173-26-004977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access